Search Results

Press Releases

KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS

April 29, 2025

·

4 min read

Press Releases

KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO PIVOTAL US PHASE III CLINICAL TRIALS FOR TG-C

July 11, 2024

·

3 min read

Drug Development

Kolon TissueGene To Expand Indications For TG-C

ACTIVITIES ARE UNDERWAY TO INITIATE US PHASE II IN HIP OSTEOARTHRITIS

December 3, 2021

·

3 min read

Drug Development

KOLON TISSUEGENE RESUMES TG-C PHASE III STUDIES IN THE U.S.

FIRST PATIENT DOSED IN RESTART OF U.S. PHASE III STUDIES IN KNEE OSTEOARTHRITIS.

December 28, 2021

·

3 min read

Drug Development

Kolon Tissuegene Announces Plans To Resume US Phase III Clinical Trial For TG-C

Kolon TissueGene, Inc. (the “Company”), a leader in advanced cell and gene therapies, announced today that the Clinical Hold issued by the FDA in April 2019 has been lifted effective April 10, 2020, and that the Company can continue with its knee osteoarthritis (OA) phase III clinical trial.

April 13, 2020

·

3 min read

Drug Development

Kolon TissueGene To Start US Phase III Clinical Trial For Invossa™

FDA GIVES KOLON TISSUEGENE THE GO-AHEAD FOR PHASE III PATIENT ENROLLMENT

July 6, 2018

·

3 min read

Drug Development

Kolon TissueGene Doses First Patient in US Phase III Clinical Trial

Kolon TissueGene, Inc. (“the Company”), a leader in advanced cell and gene therapies, announced today that it has dosed its first patient in its pivotal US Phase III clinical trials for Invossa, a cell and gene therapy in development for knee osteoarthritis (OA).

November 21, 2018

·

2 min read

Business

AllMed Announces Kathryn Kolonic as Medical Director

AllMed Healthcare Management, Inc., a leading provider of utilization management (UM) and independent review (IRO) services, today announced that Dr. Kathryn Kolonic, DO, MPH, CPHQ, has joined its executive leadership team as Medical Director and Vice President.

May 4, 2021

·

2 min read

Kolon Tissuegene

Kolon TissueGene, Inc. operates as a biopharmaceutical company. The Company develops novel advanced orthopedic disorders cell therapies, novel cell and gene therapies drugs, and other related products.

Business

Children’s Hospital of Philadelphia Appoints New Urology Division Chief

Children’s Hospital of Philadelphia has named Thomas F. Kolon, MD, as Chief of the Division of Urology.

May 2, 2023

·

3 min read